Pick's Disease, Seeding an Answer to the Clinical Diagnosis Conundrum

Area of Science:

• Neuropathology
• Neurodegenerative Diseases
• Tauopathies

Background:

• Pick's disease (PiD) is a rare neurodegenerative disorder characterized by dementia and frontotemporal lobar degeneration.
• It involves the unique aggregation of 3R tau protein into Pick bodies, but diagnosis is currently only possible post-mortem.
• The disease's rarity and lack of antemortem diagnostic tools hinder research into its etiology and pathomechanisms.

Purpose of the Study:

• To highlight the importance of studying PiD and its unique 3R tau accumulation.
• To emphasize the need for an antemortem diagnostic test for PiD to advance research and therapeutic development.
• To explore the potential of seed aggregation assays as a diagnostic tool for PiD.

Main Methods:

• Review of current understanding of Pick's disease pathology.
• Discussion of the limitations imposed by the lack of antemortem diagnostic capabilities.
• Exploration of seed aggregation assays as a potential diagnostic modality for tauopathies.

Main Results:

• Pick's disease is neuropathologically defined by 3R tau inclusions, but lacks clinical diagnostic criteria.
• Antemortem diagnosis is critical for advancing research, clinical trials, and patient recruitment for PiD.
• Seed aggregation assays show promise for diagnosing proteinopathies, including tauopathies.

Conclusions:

• Developing a clinical diagnostic assay for PiD is a vital step towards understanding the disease and improving patient outcomes.
• Adapting and optimizing seed aggregation assays to detect pathogenic 3R tau is critical for clinical diagnosis and treatment evaluation in PiD.
• Further research into seed aggregation assays could lead to the first antemortem diagnostic test for Pick's disease.